As Fate Therapeutics, Inc. trades currently, 7 analysts have their eyes on the stock whilst 2 of which rate it “Buy”, 5 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Individual stock ratings issued for FATE are highlighted below.

03/20/2017 – Broker: H.C. Wainwright Rating: New Target: 6 reiteration

03/17/2017 – Broker: Wedbush Rating: New Target: 7 reiteration

03/17/2017 – Broker: BMO Capital Markets Rating: New Target: 7 reiteration

09/22/2016 – Broker: Roth Capital Rating: New Target: 8 newcoverage

06/20/2016 – Broker: Leerink Swann Rating: New Target: 4 reiteration

12/03/2015 – Broker: Wells Fargo Rating: newcoverage

11/04/2015 – Broker: Cowen Rating: reiteration

10/06/2015 – Broker: Raymond James Rating: New Target: 8 newcoverage

05/12/2015 – Broker: Zacks Rating: New Target: 6.25 downgrade

The average target price given to the stock from the most recent broker reports is 6.61

The stock decreased -2.54% (-0.10) during the last days session, reaching 3.83 and roughly 126540 shares were bought or sold by traders.

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.